Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients,and Cryoport, Inc., a temperature-controlled logistics solutions company serving the life sciences industry, announced a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies.
This agreement with Cryoport will contribute to optimizing manufacturing and supply operations and other solutions, including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.